Document Type : Original Article(s)


1 Pathology Department, Faculty of Medicine, Zagazig University, Egypt

2 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Egypt

3 Surgical Oncology Department, Faculty of Medicine, Zagazig University, Egypt

4 Obstetrics and Gynecology Department, AlAhrar Teaching Hospital, Zagazig, Egypt



Background: Triple-negative breast cancer (TNBC) is characterized by a poor prognosis. Consequently, the current research aims to identify new therapeutic targets for TNBC patients. Trichorhinophalangeal syndrome type 1 (TRPS1), a novel GATA transcription factor, and CYP4Z1, a fatty acid hydroxylase, present potential targets for novel therapies.
Method: This retrospective study included 70 TNBC patients. The immunohistochemical expression of TRPS1, GATA3, and CYP4Z1 was evaluated. Data regarding the patient's clinical and pathological responses to chemotherapy were collected and analyzed for response assessment. SPSS version 20 software facilitated the data analysis. Quantitative variables were described using means and standard deviations, whereas categorical variables were examined using the Chi-square test or Fisher's exact test as appropriate. Survival analysis was performed using Kaplan-Meier plots, including disease-free and overall survival. A P-value of less than 0.05 was considered statistically significant.
Results: The analysis showed that 37 cases (53%) were positive for TRPS1 expression, 45 cases (65%) for GATA3, and 40 cases (57%) for CYP4Z1. There was a significant association between the expression of GATA3, TRPS1, and CYP4Z1 and various prognostic factors such as tumor size, grade, stage, lymphovascular invasion, recurrence, and mortality. Notably, the overall recurrence and progression rates were significantly correlated with the overexpression of GATA3, TRPS1, and CYP4Z1.
Conclusion: The overexpression of TRPS1, GATA3, and CYP4Z1 in TNBC patients may be novel prognostic factors for predicting tumor prognosis. Furthermore, these markers could assist in selecting patients for future therapies in both localized and metastatic breast carcinoma settings.


Reham Sameh (PubMed)


Main Subjects

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2024.99977.1966

  1. Wuelling M, Schneider S, Schröther VA, Waterkamp C, Hoffmann D, Vortkamp A. Wnt5a is a transcriptional target of Gli3 and Trps1 at the onset of chondrocyte hypertrophy. Dev Biol. 2020;457(1):104-18. doi: 10.1016/j.ydbio.2019.09.012.
  2. Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27(1):8-16. doi: 10.1097/PPO.0000000000000500.
  3. Ito T, Shimomura Y, Farooq M, Suzuki N, Sakabe J, Tokura Y. Trichorhinophalangeal syndrome with low expression of TRPS1 on epidermal and hair follicle epithelial cells. J Dermatol. 2013;40(5):396-8. doi: 10.1111/1346-8138.12111.
  4. Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in triple-negative breast cancers. Histopathology. 2017;71(1):63-71. doi: 10.1111/his.13187.
  5. Bai F, Zheng C, Liu X, Chan HL, Liu S, Ma J, et al. Loss of function of GATA3 induces basal-like mammary tumors. Theranostics. 2022;12(2):720-33. doi: 10.7150/thno.65796.
  6. Bahal D, Hashem T, Nichols KE, Das R. SLAM-SAP-Fyn: old players with new roles in iNKT cell development and function. Int J Mol Sci. 2019;20(19):4797. doi: 10.3390/ijms20194797.
  7. Liu H, Shi J, Prichard JW, Gong Y, Lin F. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Am J Clin Pathol. 2014;141(5):648-55. doi: 10.1309/AJCP0Q9UQTEESLHN.
  8. Yang L, Gong X, Wang J, Fan Q, Yuan J, Yang X, et al. Functional mechanisms of TRPS1 in disease progression and its potential role in personalized medicine. Pathol Res Pract. 2022;237:154022. doi: 10.1016/j.prp.2022.154022.
  9. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, et al. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021;34(4):710-9. doi: 10.1038/s41379-020-00692-8.
  10. Yang X, Hutter M, Goh WWB, Bureik M. CYP4Z1 - a human cytochrome P450 enzyme that might hold the key to curing breast cancer. Curr Pharm Des. 2017;23(14):2060-4. doi: 10.2174/1381612823666170207150156.
  11. Luo B, Yan D, Yan H, Yuan J. Cytochrome P450: Implications for human breast cancer. Oncol Lett. 2021;22(1):548. doi: 10.3892/ol.2021.12809.
  12. Chiliza ZE, Martínez-Oyanedel J, Syed K. An overview of the factors playing a role in cytochrome P450 monooxygenase and ferredoxin interactions. Biophys Rev. 2020;12(5):1217-22. doi: 10.1007/s12551-020-00749-7.
  13. Tran AM, Chalbatani GM, Berland L, Cruz De Los Santos M, Raj P, Jalali SA, et al. A new world of biomarkers and therapeutics for female reproductive system and breast cancers: circular RNAs. Front Cell Dev Biol. 2020;8:50. doi: 10.3389/fcell.2020.00050.
  14. Jang N, Choi JE, Kang SH, Bae YK. Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer. Virchows Arch. 2019;474(2):193-200. doi: 10.1007/s00428-018-2495-x.
  15. Koppel C, Schwellenbach H, Zielinski D, Eckstein S, Martin-Ortega M, D'Arrigo C, et al. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod Pathol. 2018;31(11):1630-44. doi: 10.1038/s41379-018-0071-1.
  16. Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Sarayra YM, Al-Saraireh RA, Al-Muhaisen GH, et al. Cytochrome 4Z1 expression is correlated with poor prognosis in patients with cervical cancer. Curr Oncol. |2021;28:3573-84. doi:10.3390/curroncol28050306.
  17. Singh A, Karnik A, Anand A. Prevalence of GATA-3 in invasive breast cancer and its significance in predicting response to neoadjuvant chemotherapy: a tertiary center experience. Int Surg J. 2021;8(6):1833-8. doi: 10.18203/2349-2902.isj20212280.
  18. Kim S, Moon BI, Lim W, Park S, Cho MS, Sung SH. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. Hum Pathol. 2016;55:190-5. doi: 10.1016/j.humpath.2016.04.013.
  19. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23(5):654-61. doi: 10.1038/modpathol.2010.38.
  20. De Lara S, Nyqvist J, Werner Rönnerman E, Helou K, Kenne Sarenmalm E, Einbeigi Z, et al. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014). BMC Cancer. 2019;19(1):187. doi: 10.1186/s12885-019-5373-2.
  21. Cornelissen LM, Drenth AP, Van Der Burg E, De Bruijn R, Pritchard CEJ, Huijbers IJ, et al. TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. Genes Dev. 2020;34:179-93. doi: 10.1101/gad.331371.119.
  22. Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Sarayra YM, Al-Saraireh RA, Al-Muhaisen GH, et al. Cytochrome 4Z1 expression is correlated with poor prognosis in patients with cervical cancer. Curr Oncol. 2021;28(5):3573-84. doi: 10.3390/curroncol28050306.
  23. Al-Esawi NSE, Geeran ARM, Alajeely MHJ, Al-Isawi AOJ. Expression of CYT4Z1 in breast carcinoma; correlating with clinicopathological parameters. Biomed Pharmacol J. 2020;13(1).
  24. Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Sarayreh S, Almuhaisen GH, Alnawaiseh N, et al. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep. 2021;11(1):5581. doi: 10.1038/s41598-021-85188-4.
  25. Wu W, Warner M, Wang L, He WW, Zhao R, Guan X, et al. Drivers and suppressors of triple-negative breast cancer. Proc Natl Acad Sci U S A. 2021;118(33):e2104162118. doi: 10.1073/pnas.2104162118.
  26. Kowalski JP, McDonald MG, Pelletier RD, Hanenberg H, Wiek C, Rettie AE. Design and characterization of the first selective and potent mechanism-based inhibitor of cytochrome p450 4z1. J Med Chem. 2020;63(9):4824-36. doi:10.1021/acs.jmedchem.0c00101.